Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression
dc.contributor.author | Razi, E. D. | en |
dc.contributor.author | Kalogeras, K. T. | en |
dc.contributor.author | Kotoula, V. | en |
dc.contributor.author | Eleftheraki, A. G. | en |
dc.contributor.author | Nikitas, N. | en |
dc.contributor.author | Kronenwett, R. | en |
dc.contributor.author | Timotheadou, E. | en |
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Wirtz, R. M. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Televantou, D. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Razi, E. D. | en |
dc.creator | Kalogeras, K. T. | en |
dc.creator | Kotoula, V. | en |
dc.creator | Eleftheraki, A. G. | en |
dc.creator | Nikitas, N. | en |
dc.creator | Kronenwett, R. | en |
dc.creator | Timotheadou, E. | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Gogas, H. | en |
dc.creator | Wirtz, R. M. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Televantou, D. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:53:02Z | |
dc.date.available | 2018-06-22T09:53:02Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41623 | |
dc.description.abstract | Background: Chemokines are important in cell migration and are thought to play a key role in metastasis. We explored the prognostic significance of C-X-C ligand-motif (CXCL) 12, CXCL13, and receptor (CXCR) 5 on disease-free survival (DFS) and overall survival (OS) in early breast cancer. Methods: A total of 595 patients at high risk for early breast cancer were treated in a 2-arm trial (HE10/97) with dose-dense sequential epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with or without paclitaxel. RNA was extracted from 321 formalin-fixed paraffin-embedded primary tumor tissue samples and quantitative reverse-transcriptase polymerase chain reaction was used to assess messenger RNA (mRNA) expression of CXCL12, CXCL13, and CXCR5; estrogen receptor; progesterone receptor (PgR); microtubule-associated protein tau and human epidermal growth factor receptor 2 (HER2). Results: CXCL13 and CXCR5 were found to be negatively associated with estrogen receptor and microtubule-associated protein tau mRNA expression and with dense lymphocytic infiltration, and were positively associated with nuclear grade. Only CXCL13 was positively associated with HER2. Multivariate analysis revealed an association between high CXCL13 mRNA expression and improved DFS (hazard ratio [HR] 0.48 [95% CI, 0.25-0.90]; Wald, P =.023) but not OS; whereas high CXCL12 expression was significantly associated with increased OS (HR 0.53 [95% CI, 0.33-0.85]; Wald, P =.009). In the HER2 mRNA overexpressing subgroup, high CXCL13 mRNA expression was associated with improved DFS (P <.001), whereas high CXCR5 was associated with increased DFS and OS (P =.004 and P =.049, respectively). Conclusions: The CXCL13-CXCR5 axis is associated with classic determinants of poor prognosis, such as high grade, hormone receptor negativity, and axillary node involvement. Interestingly, this chemokine axis seems to be strongly associated with improved outcome in patients with HER2+ disease. © 2012 Elsevier Inc. | en |
dc.language.iso | eng | en |
dc.source | Clinical Breast Cancer | en |
dc.subject | Article | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer patient | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Cancer survival | en |
dc.subject | Paclitaxel | en |
dc.subject | Human tissue | en |
dc.subject | Cancer staging | en |
dc.subject | Disease free survival | en |
dc.subject | Granulocyte colony stimulating factor | en |
dc.subject | Overall survival | en |
dc.subject | Cancer prognosis | en |
dc.subject | Hazard ratio | en |
dc.subject | Multivariate analysis | en |
dc.subject | Outcome assessment | en |
dc.subject | Epirubicin | en |
dc.subject | Protein expression | en |
dc.subject | Cancer risk | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Quantitative assay | en |
dc.subject | Messenger rna | en |
dc.subject | Reverse transcription polymerase chain reaction | en |
dc.subject | Epidermal growth factor receptor 2 | en |
dc.subject | Cancer tissue | en |
dc.subject | Paraffin | en |
dc.subject | Tau protein | en |
dc.subject | Estrogen receptor | en |
dc.subject | Progesterone receptor | en |
dc.subject | Formaldehyde | en |
dc.subject | Rna extraction | en |
dc.subject | Chemokine receptor cxcr4 | en |
dc.subject | Chemokine receptor cxcr5 | en |
dc.subject | Chemokines | en |
dc.subject | Cxcl12 | en |
dc.subject | Cxcl13 | en |
dc.subject | Cxcl13 chemokine | en |
dc.subject | Cxcr5 | en |
dc.subject | Human epidermal growth factor receptor 2 | en |
dc.subject | Protein motif | en |
dc.subject | Tissue fixation | en |
dc.subject | Tumor associated leukocyte | en |
dc.title | Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.clbc.2012.03.006 | |
dc.description.volume | 12 | |
dc.description.issue | 3 | |
dc.description.startingpage | 183 | |
dc.description.endingpage | 193 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kotoula, V. [0000-0002-8657-9732] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-8657-9732 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |